What Packaging Compliance Covers for a Cosmetic Product
Three frameworks cover almost everything, and knowing which one a rule comes from makes the rest easier to navigate.
The FD&C Act (1938) defines what counts as a cosmetic. The Fair Packaging and Labeling Act (1967) sets the identity, net quantity, and responsible-party statements every consumer product carries. MoCRA (2022) is the biggest update since 1938, and most of what it added never appears on the pack.
Two ground rules for what follows. Each rule is marked as a requirement or a best practice, because the two are genuinely different, and guidance that blurs them sends brands to the wrong places. And nothing here establishes that your product is compliant: that depends on your formulation, your claims, and your markets. This is a list of what to check and who to ask.
The Mandatory Label Elements: Rules 1 to 4
These four are required on virtually every retail cosmetic sold in the US, and together they consume more panel space than most layouts assume.
1. Statement of Identity (Requirement, 21 CFR 701.11)
The product’s common or usual name, its descriptive name, or an illustration of how it is used, appearing on the principal display panel as one of its principal features, in bold type reasonably proportional to everything else on that panel.
The word “principal” is doing real work there. A statement of identity set small enough to preserve a clean front panel is a compliance issue, not an aesthetic choice.
2. Net Quantity of Contents (Requirement, 21 CFR 701.13)
Also on the principal display panel, and here the regulation is unusually specific about placement: it must sit within the bottom 30% of the panel, with an exemption where the PDP is 5 square inches or smaller.
Minimum type size scales with panel area under 701.13(i):
A dual US and metric declaration is permitted under 701.13(r) rather than required by it, which is worth knowing before treating it as an obligation.
The design consequence is direct: the bottom third of your front panel is spoken for.
3. Ingredient Declaration (Requirement, 21 CFR 701.3)
Every ingredient, in descending order of predominance, with one permitted simplification. Ingredients present above 1% must appear in order; those at or below 1% may appear in any order after them; color additives come last under 701.3(g), regardless of concentration.
Minimum type size is 1/16 inch. The declaration may appear on any information panel, and FDA guidance treats the bottom of the package as generally not acceptable for it. That last point removes a surface that carton layouts routinely assume is free.
Note that “information panel” is packaging convention rather than a defined regulatory term for cosmetics. Part 701 defines the principal display panel precisely and does not define its counterpart the way the OTC drug rules do.
4. Name and Place of Business (Requirement, 21 CFR 701.12)
The corporate name and address of the manufacturer, packer, or distributor: street address, city, state, and ZIP code. If the party named did not manufacture the product, the statement has to be qualified, typically as “Manufactured for” or “Distributed by”.
This is the rule most often satisfied incorrectly rather than omitted, usually by a brand printing its own name unqualified on a product made by a contract manufacturer.
What MoCRA Added: Rules 5 to 8
MoCRA’s obligations are mostly regulatory rather than typographic, which is exactly why they get missed by teams thinking about packaging. The scale of the system it created is worth seeing: as of 6 January 2026 it held 14,299 active facility registrations and 992,907 active product listings.
5. Facility Registration (Requirement)
Every facility that manufactures or processes cosmetics for US distribution must be registered with FDA, with renewal every two years.
6. Product Listing (Requirement)
Each marketed cosmetic product must be listed with FDA, including its ingredients, with the listing updated annually.
7. Safety Substantiation (Requirement)
Every marketed cosmetic must have adequate substantiation of safety on file. This is the provision with the widest reach, because it applies to all products rather than to a category, and because it is a documentation obligation with no visible output on the pack.
It also has a consequence worth flagging for anyone working from older guidance. 21 CFR 740.10 historically allowed a product whose safety had not been substantiated to carry a warning saying so. Whether that route survives MoCRA’s mandatory substantiation is genuinely unsettled, and it should not be treated as a live compliant option without current legal advice.
8. Adverse Event Reporting (Requirement)
Serious adverse events must be reported to FDA within 15 business days, with records retained for six years, or three for qualifying small businesses.
Two MoCRA rules are still pending and must not be planned around as final. The fragrance allergen labeling rule missed its 29 June 2024 statutory deadline; a proposed rule is now targeted for May 2026, with a final rule considered unlikely before 2027. The Good Manufacturing Practice rule was also still pending as of January 2026. Both will affect packaging when they land, and neither is text you can write today.
Warnings, Drug Status, State Law, and Claims: Rules 9 to 12
9. Warning Statements (Requirement Where Applicable, 21 CFR Part 740)
Part 740 sets verbatim warnings for specific product types: aerosols under 740.11, feminine deodorant sprays under 740.12, foaming detergent bath products under 740.17, and coal tar hair dyes under 740.18. Section 740.1 additionally gives FDA general authority to require a warning wherever one is necessary to prevent a health hazard.
These are prescribed text rather than paraphrasable guidance, which makes them a fixed block in a layout rather than a flexible one.
10. The Drug-Status Trap (Requirement Where Triggered, 21 CFR 201.66)
This is the single most expensive surprise in cosmetic packaging, and it is triggered by a claim rather than by a formulation change.
Sunscreens, anti-dandruff products, antiperspirants (though not deodorants), acne treatments, and anti-caries toothpastes are OTC drugs as well as cosmetics. That status requires a Drug Facts panel under 21 CFR 201.66, a regulation that governs format as strictly as content: fixed heading order, minimum type sizes, required barlines and hairlines. Sunscreens carry further content requirements under 21 CFR Part 352 and 201.327.
The packaging consequence is structural. A Drug Facts block is a large, rigid, non-negotiable element that must coexist on the same carton with every cosmetic element already listed above. Adding an SPF claim late in development is not a copy change. It is a panel-layout problem, and often a carton-size problem.
11. State Law (Requirement Where You Ship)
Federal compliance is not sufficient, and California sets the pace.
Proposition 65 requires a warning before knowingly exposing a person in California to a listed chemical. Bisphenol S and N-Methyl-N-Formylhydrazine were added on 5 December 2025. Short-form warnings must now identify at least one chemical per exposure endpoint at a minimum of 6 point, with full compliance required by 1 January 2028. This area is actively litigated: on 11 August 2025 a federal court issued a permanent injunction against the titanium dioxide warning for cosmetics on First Amendment grounds, so the current position is evolving rather than settled.
Ingredient bans run on their own timetable. AB 2762 banned 24 ingredients from 1 January 2025, AB 496 bans 26 more from 1 January 2027, and SB 312 requires fragrance ingredient disclosure to the California Department of Public Health.
Extended producer responsibility now exists in seven states, though only Oregon and Colorado currently have live producer fee obligations. EPR runs on a different rhythm from labeling law: the first question is whether your revenue and volume make you an obligated producer at all, and if they do, the work is registering with the state’s producer responsibility organization and reporting packaging data on a schedule. The material and recyclability decisions behind those obligations are covered in our guides to what makes packaging recyclable and PCR packaging.
12. Claims and the FTC (Requirement, With a Best-Practice Layer)
Clean, natural, hypoallergenic, dermatologist tested, and cruelty-free have no legal definition from either FDA or FTC. That is not permission to use them freely: the FTC can act against any claim that misleads in context, so an undefined term still has to be substantiated against how a reasonable consumer would read it.
For animal testing, Leaping Bunny is the recognized third-party certification, and using a logo designed to resemble it without holding it is itself a violation.
Environmental claims fall under the FTC’s Green Guides, which have been under revision since 2022 with an update expected in 2026. Specific numeric thresholds circulating as rules of thumb for terms like “recyclable” are not reliable while that revision is open. Best practice: qualify environmental claims specifically rather than generally, and hold the substantiation before the claim goes to plate.
What Compliance Costs You on the Carton
Two things about compliance only show up once a carton is being made.
The barcode carries a penalty no regulator issues. A UPC-A needs a 9X quiet zone each side, and print quality is graded under ISO/IEC 15416: GS1’s floor is grade C, but many major retailers require grade B. Macy’s charges $50 per receipt plus 50% of merchandise cost for barcode failures. None of that is FDA, and none of it appears on a regulatory checklist. It is enforced at the receiving dock, after the cartons are printed.
Timing sets the cost of a copy change, not content. Before artwork is signed, adding a Prop 65 warning or resizing type is a text edit. Afterwards, once plates are imaged, the same change means re-running prepress, new plates, and possibly scrapped substrate. The requirement did not get harder. The stage did.
Worth adding: the mandatory copy above takes up more of a small carton than most layouts assume, which makes this a structural conversation rather than a final proofreading pass.
The Pre-Launch Checklist
Run in this order, because each step constrains the next.
- Classify the product. Cosmetic, OTC drug, or both. This decides whether a Drug Facts panel is in the layout, and it has to be settled before the carton is sized.
- Confirm MoCRA status. Facility registered, product listed, safety substantiation documented and on file.
- Lock identity and net quantity against the 701.13(i) type-size table for your actual panel area, with the net quantity inside the bottom 30%.
- Finalize the ingredient declaration against the current formulation, checked against California’s ingredient bans for the markets you ship to.
- Check Part 740 for any warning your product type triggers, and reproduce it verbatim.
- Check state obligations: Prop 65 exposure, ingredient bans, EPR registration where required.
- Substantiate every claim on the pack, including the ones that feel like adjectives.
- Confirm barcode specifications with the retailer, not with a generic standard: symbol size, quiet zones, and the print-quality grade they require.
- Route the artwork through compliance review before plates are made. This is the highest-return step on the list, because it is the last point at which every item above is still an edit.
How Arkay Works With Regulated Copy
With more than 100 years of manufacturing behind it and four generations of family ownership, Arkay’s role here is specific and worth stating precisely: Arkay does not certify compliance, and no carton manufacturer can. Compliance depends on formulation, intended use, and claims, none of which sit with the printer.
What a manufacturer can do is catch the problems that are physical rather than legal, and catch them while they are still inexpensive to fix.
Prepress and platemaking run in-house at the Roanoke, VA facility, which is BRCGS packaging safety certified, so a copy change is reconciled against the dieline and the barcode specification before a plate exists rather than after. That matters for exactly the reason described above: the cost of a compliance change is set almost entirely by which side of platemaking it lands on. Our guide to packaging quality assurance covers where those checks sit in a run.
Where mandatory copy will not fit at its required type sizes, that is a structural question rather than a design one, and it gets answered at the Design Studio in Hauppauge, NY, where a brand team can bring a layout problem and leave with a physical mock-up, typically within a week. Arkay’s cosmetics packaging work and its production capabilities exist to support that conversation alongside a brand’s regulatory counsel, not in place of it. Substrate choice interacts with all of this too, and our guide to paperboard packaging covers how caliper and finish affect the legibility of small mandatory type.
Check the Copy Before the Plates
Let us look at the layout while it is still a proof.
Send the artwork and the panel dimensions. We will tell you whether the mandatory copy fits at the sizes it has to be, whether the net quantity statement is where it needs to sit, whether the barcode will grade at a receiving dock, and whether the folding carton is the right size for everything the product is legally required to say.
We will not tell you whether your product is compliant. Your regulatory team does that. We will make sure that when they sign it, it fits.
Reach out to Arkay’s team with a layout, or with a question about one.
Frequently Asked Questions
Does the FDA approve cosmetic labels before market?
No. Cosmetics other than color additives are not subject to FDA premarket approval, and no agency signs off on a label before it prints. Oversight is post-market: FDA acts on products already being sold, through warning letters, seizures, and now the mandatory adverse event reporting MoCRA introduced. The practical implication is that nobody external is going to catch a labeling error for you, which is why the review has to happen before artwork is frozen rather than after a complaint arrives.
What is the difference between a cosmetic and an OTC drug for labeling?
Intended use, expressed through claims and active ingredients, not through how the product feels or where it sits in a store. A moisturizer is a cosmetic; the same moisturizer with an SPF claim is also an OTC drug, and so are anti-dandruff shampoos, antiperspirants, acne treatments, and anti-caries toothpastes. Crossing that line adds a Drug Facts panel under 21 CFR 201.66, which specifies format as well as content: fixed heading order, minimum type sizes, and required barlines. It is a fixed block that has to coexist with every cosmetic element already on the carton.
Is cruelty-free or dermatologist-tested legally regulated?
Neither has a legal definition from FDA or FTC, and the same is true of clean, natural, and hypoallergenic. That does not make them safe to use freely: the FTC can act against any claim that is misleading in context, so an unqualified term still has to be substantiated against how a reasonable consumer would read it. For animal testing specifically, Leaping Bunny is the recognized third-party certification, and using a logo designed to resemble it without holding it is itself a violation.
Do I need to list every ingredient on the carton?
Yes, for retail cosmetics, in descending order of predominance, with a permitted simplification: ingredients above 1% must appear in order, those at or below 1% may appear in any order after them, and color additives come last regardless. Minimum type size is 1/16 inch. The declaration can sit on any information panel, but FDA guidance treats the bottom of the package as generally not acceptable, which removes a panel that carton layouts often assume is available.
What is Prop 65 and does it apply to cosmetic packaging?
California’s Proposition 65 requires a warning before knowingly exposing anyone in California to a listed chemical, and because that warning usually appears on the pack it becomes a packaging problem. The list changes: bisphenol S was added in December 2025, and short-form warnings now have to name at least one chemical per exposure endpoint at a minimum of 6 points, with full compliance required by 1 January 2028. It is also actively litigated, and a federal court permanently enjoined the titanium dioxide warning for cosmetics in August 2025. Treat the current position as evolving rather than settled.
Can a packaging supplier confirm my label is compliant?
No, and any supplier that says otherwise is describing a service it cannot provide. Compliance depends on formulation, intended use, claims, and the markets a product ships into, none of which a carton manufacturer controls or can verify. What a manufacturer can do is different and still valuable: confirm whether mandatory copy fits at the required type sizes, whether the net quantity statement falls inside the bottom 30% of the panel, whether the barcode has its quiet zones, and whether a change can still be made before plates are imaged.
